Mirum Pharmaceuticals Stock Price, News & Analysis

Mirum Pharmaceuticals (NASDAQ: MIRM) reported preliminary unaudited full-year 2025 results and 2026 outlook. 2025 net product sales were approximately $520 million, above the top of guidance. Management expects 2026 net product sales of $630M–$650M. 2025 LIVMARLI net sales were ~$359M (including ~$243M US), +69% YoY; CHOLBAM and CTEXLI combined ~$161M, +31% YoY. Year-end cash, cash equivalents and investments are expected to be ~$392M vs $292.8M a year earlier. Key upcoming catalysts: volixibat VISTAS PSC topline Q2 2026, LIVMARLI EXPAND topline Q4 2026, and proposed Bluejay acquisition with AZURE HDV data in H2 2026 (pending close).

Enthorin Therapeutics announced that licensing partner Mirum Pharmaceuticals (NASDAQ: MIRM) initiated the BLOOM Phase 2 clinical study of MRM-3379 (formerly ENT-3379) in Fragile X syndrome in December. MRM-3379 is described as an orally available, highly brain-penetrant, selective PDE4D inhibitor designed to enhance cAMP signaling. The compound was discovered at Dart Neuroscience and advanced through Phase 1; preclinical data in an FMR1 knockout mouse reportedly showed improved cognition and reduced behavioral deficits. Enthorin acknowledged the clinical and scientific teams involved in the decade-long research and development leading to this patient-trial milestone.

Mirum Pharmaceuticals (NASDAQ: MIRM) will present at the 44th Annual J.P. Morgan Healthcare Conference in San Francisco on January 14, 2026 at 11:15 a.m. PT. The company said the presentation and subsequent Q&A will be webcast live and accessible via the Investors section of Mirum’s corporate website.

This provides investors and analysts live access to Mirum’s corporate presentation and management Q&A during the conference.

Mirum Pharmaceuticals (Nasdaq: MIRM) entered a subscription agreement with entities associated with TCGX for a private placement of 1,000,000 common shares at $68.48 per share, raising approximately $68.5 million in gross proceeds.

Combined with a previously announced $200 million private placement, the proceeds are intended to fund clinical development and commercial activities related to the proposed acquisition of Bluejay Therapeutics. Both private placements are expected to close concurrently with the proposed Bluejay acquisition in Q1 2026, subject to regulatory approval and customary closing conditions. The shares are being sold in a private transaction and are not registered under the Securities Act; Mirum and the investors executed registration rights that will become effective at closing.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced inducement equity awards granted on December 10, 2025 to eight new employees under its 2020 Inducement Plan pursuant to Nasdaq Listing Rule 5635(c)(4).

The Compensation Committee granted non‑qualified stock options to purchase 15,820 shares and 7,840 restricted stock units (RSUs). Each option has an exercise price of $64.67, equal to Mirum’s closing price on December 10, 2025. Options vest over four years (25% at one year, then monthly over 36 months); RSUs vest over three years (33% each anniversary), both subject to continued service and the applicable award agreements.

Mirum Pharmaceuticals (Nasdaq: MIRM) entered a definitive agreement to acquire Bluejay Therapeutics, gaining worldwide rights to brelovitug, a late‑stage monoclonal antibody for chronic hepatitis delta virus (HDV) with Breakthrough Therapy and PRIME designations.

The deal consideration is $250M cash + $370M in Mirum stock (priced at $71.2085/share) plus up to $200M in sales‑based cash milestones. Mirum also arranged a private placement to raise ~$200M concurrent with closing. AZURE Phase 3 top‑line data expected 2H 2026 with potential BLA submission and launch in 2027. Closing expected Q1 2026, subject to approvals and customary conditions.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced first patient enrollment in the BLOOM Phase 2 study of oral MRM-3379 for Fragile X syndrome (FXS).

The randomized trial will evaluate safety, tolerability, and potential clinical benefit in males with a confirmed FMR1 mutation. Top-line data are expected in 2027. The company noted preclinical cognitive and behavioral improvements and favorable tolerability in healthy volunteers. Interested participants can find the study under NCT07209462 on clinicaltrials.gov.

Mirum Pharmaceuticals (Nasdaq: MIRM) will participate in two investor conferences the week of December 2, 2025: the 8th Annual Evercore HealthCONx Conference with a company presentation on Tuesday, December 2 at 2:10 p.m. ET, and Citi’s 2025 Global Healthcare Conference on Wednesday, December 3. Investors can access webcast links and additional information via the company’s Investors and Media webpage.

Mirum Pharmaceuticals (Nasdaq: MIRM) announced on November 10, 2025 that its Compensation Committee granted inducement awards to 11 new employees under the 2020 Inducement Plan in accordance with Nasdaq Listing Rule 5635(c)(4).

The awards consist of 53,500 non-qualified stock options and 27,950 restricted stock units (RSUs). Each option has an exercise price of $69.71, equal to Mirum’s closing price on November 10, 2025. Options vest over four years with 25% vesting at the first anniversary and the remainder vesting monthly over 36 months; RSUs vest over three years with 33% vesting on each anniversary, in each case subject to continued service and the terms of the 2020 Inducement Plan and applicable award agreements.